HK Stock Market Move | JACOBIO-B(01167) rose more than 6% during trading, subsidiary receives first payment of 125 million yuan, combination therapy featured in "The Lancet"

JACOBIO-B (01167) rose more than 6% intraday, and as of the time of publication, it was up 5.51% to HK$8.04, with a turnover of HK$81.525 million. On the news front, JACOBIO announced that its subsidiary Beijing JACOBIO has received an initial payment of RMB 125 million from Haisong Capital. This payment has further strengthened the group's cash reserves and will provide support for the company's innovative cancer therapy pipeline. Furthermore, JACOBIO recently announced that the results of the Phase I/IIa clinical study of the company's self-developed KRAS G12C inhibitor glecirasib in combination with the SHP2 inhibitor JAB-3312 (sitneprotafib) have been officially published in the top international medical journal "The Lancet Respiratory Medicine" (impact factor 32.8). This is the first systematic clinical data on the combination therapy of KRAS G12C and SHP2 dual oral small molecules to be published in this authoritative journal worldwide.